Daihong Liu
Chinese PLA General Hospital · Chines PLA General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daihong Liu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:22 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07450391 · EBV-AST Cell Injection for EBV-Associated Lymphoproliferative DisordersDaihong Liu · recruiting · Epstein-Barr Virus-Associated Lymphoproliferative Disorders, EBV-Positive Lymphoma · study chair
- Ph1NCT06135922 · Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV InfectionChinese PLA General Hospital · recruiting · EBV-associated Hemophagocytic Lymphohistiocytosis, EBV Infection · principal investigator
- Ph1NCT06119256 · Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCTChinese PLA General Hospital · recruiting · EBV Infection After Allogenic HSCT · principal investigator
- Ph2NCT06084819 · Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaChinese PLA General Hospital · recruiting · Relapsed/Refractory Acute Myeloid Leukemia · study chair
- Ph2NCT06068621 · Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid LeukemiaChinese PLA General Hospital · completed · Acute Myeloid Leukemia · study chair
- Ph2NCT05659992 · Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid LeukemiaChinese PLA General Hospital · completed · Acute Myeloid Leukemia · study chair
- Ph1NCT05270772 · CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALLChinese PLA General Hospital · unknown · CD19+ Relapse/Refractory B-ALL · principal investigator
- Ph2NCT05214066 · Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTChinese PLA General Hospital · unknown · aGVHD, cGVHD · study director
- Ph3NCT05166967 · Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell TransplantationChinese PLA General Hospital · completed · Haploidentical Hematopoietic Stem Cell Transplantation · principal investigator
- Ph1NCT05140187 · CMV-TCR-T Cells for CMV Infection After Allogenic HSCTChinese PLA General Hospital · unknown · CMV Infection After Allogenic HSCT · principal investigator
- Ph2NCT05088226 · Ruxolitinib and Chidamide Intensified Bu/CY Conditioning RegimenChinese PLA General Hospital · recruiting · Peripheral Blood Stem Cell Transplantation · principal investigator
- Ph1/Ph2NCT05075681 · Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic LymphomaChinese PLA General Hospital · unknown · Peripheral Blood Stem Cell Transplantation · principal investigator
- Ph1/Ph2NCT04582604 · Ruxolitinib and Decitabine for High Risk Hematological MalignanciesChinese PLA General Hospital · unknown · Peripheral Blood Stem Cell Transplantation · principal investigator
- Ph1/Ph2NCT04397367 · Low Dose Ruxolitinib in Combination With MethylprednisoloneChinese PLA General Hospital · completed · aGVHD, Stem Cell Transplant Complications · principal investigator
- N/ANCT04284904 · Role of aGVHD Biomarkers on aGVHD RisksChinese PLA General Hospital · completed · GVHD,Acute, Biomarker · principal investigator
- Ph2NCT04061876 · First Line Therapy for High Risk Acute GVHDChinese PLA General Hospital · completed · aGVHD, Stem Cell Transplant Complications · study director
- Ph4NCT02784561 · Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell TransplantationChinese PLA General Hospital · unknown · Leukemia · study director
- Ph4NCT02677181 · Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTChinese PLA General Hospital · completed · aGVHD · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:22 UTC. The ranking covers the 200 most relevant of 981 PubMed records, and a shared surname and initials can bring in a namesake. All 981 on PubMed
- Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak.Cancer Discov · 20201,183 citationsRCR 55.1
- 570 citationsRCR 33.6
- [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].Zhejiang Da Xue Xue Bao Yi Xue Ban · 2020446 citationsRCR 24.1
- Calorie Restriction with or without Time-Restricted Eating in Weight Loss.N Engl J Med · 2022412 citationsRCR 33.5
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.J Clin Oncol · 2019351 citationsRCR 12.8
- Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.JAMA Ophthalmol · 2018328 citationsRCR 17.7
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.N Engl J Med · 2018309 citationsRCR 10.4
- Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.Diabetes Care · 2015257 citationsRCR 9.5
- Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.N Engl J Med · 2021247 citationsRCR 17.3
- Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes.Diabetes Care · 2015159 citationsRCR 5.9